CorMedix Inc. CRMD
Set alert
At close · Oct 30
After hours · Oct 30, 7:58 PM ET
- YTD
- -51.03%
- 1 year
- -50.99%
- Open
- 7.68
- Prev close
- 7.64
- Mkt cap
- 443.89M
- Vol
- 7.02M
- Avg vol
- 1.23M
- EPS
- 2.05
- P/E
- 2.78
- Div yield
- 0.00%
More statistics
- Low
- 5.63
- High
- 7.68
- Forward P/E
- 17.54
- Beta
- 1.58
- Short ratio
- 5.12
- Inst. own
- 31.92%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.35
- 200-d avg
- 6.57
- 1y target
- 16.25
5D chart
Signals (85)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:15 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:15 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:45 PM | 4 days ago |
| RSI: Overbought | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:20 PM | 6 days ago |
| RSI: Oversold | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
News
1 week ago defenseworld.net
CorMedix (NASDAQ:CRMD) vs. MediciNova (NASDAQ:MNOV) Financial Analysis
CorMedix (NASDAQ: CRMD - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
-
1 week ago benzinga.com
CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027
CorMedix Therapeutics (NASDAQ:CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO®…
1 week ago globenewswire.com
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New…
-
2 weeks ago benzinga.com
Actinium Pharmaceuticals Appoints Dr. Matt David As CFO
Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc.…
2 weeks ago prnewswire.com
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…
3 weeks ago zacks.com
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better…
-
1 month ago benzinga.com
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15
Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform rating and announces Price Target of $15.
1 month ago zacks.com
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
2 months ago globenewswire.com
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for…
2 months ago zacks.com
CorMedix (CRMD) Upgraded to Buy: Here's Why
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 months ago zacks.com
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.
2 months ago zacks.com
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
2 months ago seekingalpha.com
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
CorMedix Q2 Earnings Call Highlights
CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted…
2 months ago benzinga.com
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-quarter results. The broader market was also slightly higher, with S&P 500 futures up 0.2%.
2 months ago benzinga.com
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.
2 months ago benzinga.com
Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday
Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% after being acquired by Thoma Bravo and reporting strong Q2 results. Other top gainers include Omeros…
2 months ago zacks.com
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.28 per share a year ago.
2 months ago benzinga.com
Full Transcript: Cormedix Q2 2026 Earnings Call
On Thursday, Cormedix (NASDAQ:CRMD) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
-
2 months ago benzinga.com
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $334.089 million estimate.
2 months ago globenewswire.com
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒…
3 months ago globenewswire.com
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before…
3 months ago benzinga.com
Frequency Electronics Posts Weak Q4 Results, Joins AST SpaceMobile And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
US stock futures mixed, Dow futures up 0.2%. Frequency Electronics (FEIM) shares down 8.3% after reporting Q4 losses. Other stocks also lower in pre-market.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $14 to $13.
4 months ago benzinga.com
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock, Optimum Communications, Cronos, and others also drop.
4 months ago zacks.com
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
4 months ago zacks.com
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
4 months ago zacks.com
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
4 months ago globenewswire.com
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of…
5 months ago seekingalpha.com
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to…
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
9 months ago benzinga.com
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
9 months ago benzinga.com
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
11 months ago benzinga.com
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday
-
11 months ago benzinga.com
Earnings Scheduled For November 12, 2025
Earnings Scheduled For November 12, 2025
11 months ago benzinga.com
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More
Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.
1 year ago benzinga.com
Hedge Fund Elliott Management's Q2 Moves Include Positions Tied To S&P 500, Nasdaq, Nvidia (CORRECTED)
Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions tied to major indexes and tech leaders like Nvidia while exiting several prior holdings.
1 year ago benzinga.com
Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.
-
1 year ago benzinga.com
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago benzinga.com
Tesla, SpartanNash, Standard BioTools And Other Big Stocks Moving Higher On Monday
Tesla, SpartanNash, Standard BioTools And Other Big Stocks Moving Higher On Monday
1 year ago benzinga.com
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
1 year ago benzinga.com
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
-
2 years ago benzinga.com
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday